NCT00364923已完成2 期
A Multi-Center, Phase 2, Open-Label Study of (RS)-10-Propargyl-10-Deazaaminopterin (Pralatrexate) With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 115
- 试验地点
- 64
- 主要终点
- Response Rate Per Independent Central Review
研究概览
简要总结
Primary
• Determine the efficacy of pralatrexate with concurrent vitamin B12 and folic acid supplementation when administered to patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)
Secondary
- Determine the safety of pralatrexate with concurrent vitamin B12 and folic acid supplementation when administered to patients with relapsed or refractory PTCL
- Determine the pharmacokinetic (PK) profile of pralatrexate when administered with vitamin B12 and folic acid supplementation
详细描述
This is a Phase 2, single arm, non-randomized, open-label, multi-center study designed to evaluate the safety and effectiveness of pralatrexate when administered with vitamin B12 and folic acid supplementation to patients with relapsed or refractory PTCL.
Pralatrexate will be given over 3-5 minutes intravenously (IV), which means through a vein. If pralatrexate is tolerated well, the patient will receive IV injections of pralatrexate every week for 6 weeks, followed by 1 week without receiving pralatrexate. These 7 week cycles will be repeated depending on response and tolerability.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically/cytologically confirmed PTCL, using the Revised European American Lymphoma (REAL) World Health Organization (WHO) disease classification:
- •T/Natural Killer (T/NK) cell leukemia/lymphoma
- •Adult T-cell lymphoma/leukemia (human T-cell leukemia virus [HTLV] 1+)
- •Angioimmunoblastic T cell lymphoma
- •Blastic Natural Killer (NK) lymphoma (with skin, lymph node, or visceral involvement)
- •Anaplastic large cell lymphoma, primary systemic type
- •PTCL - unspecified
- •T/NK-cell lymphoma - nasal
- •Enteropathy-type intestinal lymphoma
- •Hepatosplenic T cell lymphoma
- •Extranodal peripheral T/NK-cell lymphoma - unspecified
- •Subcutaneous panniculitis T-cell lymphoma
- •Transformed mycosis fungoides
- •Documented progression of disease after at least 1 prior treatment. Patients may not have received experimental therapy as their only prior therapy. Patient has at least 1 biopsy from initial diagnosis or in the relapsed setting to confirm the diagnosis of PTCL. Patient has recovered from the toxic effects of prior therapy. Patients treated with monoclonal antibody therapy may be enrolled regardless of the time frame of the therapy if they have progression of disease.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status ≤
- •≥ 18 years of age.
- •Adequate hematological, hepatic, and renal function.
- •Women of childbearing potential must agree to practice a medically acceptable contraceptive regimen from study treatment initiation until at least 30 days after the last administration of pralatrexate and must have a negative serum pregnancy test within 14 days prior to the first day of study treatment. Patients who are postmenopausal for at least 1 year or are surgically sterilized do not require this test.
- •Men who are not surgically sterile must agree to practice a medically acceptable contraceptive regimen from study treatment initiation until at least 90 days after the last administration of pralatrexate.
- •Patient has given written informed consent.
排除标准
- •Patient has:
- •Precursor T/NK neoplasms, with the exception of blastic NK lymphoma
- •T cell prolymphocytic leukemia (T-PLL)
- •T cell large granular lymphocytic leukemia
- •Mycosis fungoides, other than transformed mycosis fungoides
- •Sézary syndrome
- •Primary cutaneous CD30+ disorders: Anaplastic large cell lymphoma and lymphomatoid papulosis
- •Active concurrent malignancy (except non melanoma skin cancer or carcinoma in situ of the cervix). If there is a history of prior malignancy, the patient must be disease free for greater than or equal to 5 years.
- •Congestive heart failure Class III/IV according to the New York Heart Association's Heart Failure Guidelines.
- •Uncontrolled hypertension.
- •Human immunodeficiency virus (HIV)-positive diagnosis and is receiving combination anti-retroviral therapy.
- •Patient has, or history of, brain metastases or central nervous system (CNS) disease.
- •Patient has undergone an allogeneic stem cell transplant.
- •Patient has relapsed less than 75 days from time of an autologous stem cell transplant.
- •Active uncontrolled infection, underlying medical condition including unstable cardiac disease, or other serious illness that would impair the ability of the patient to receive protocol treatment.
- •Major surgery within 2 weeks of study entry.
- •Receipt of any conventional chemotherapy or radiation therapy (RT) within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to study treatment or planned use during the course of the study.
- •Receipt of corticosteroids within 7 days of study treatment, unless patient has been taking a continuous dose of no more than 10 mg/day of prednisone for at least 1 month.
- •Use of any investigational drugs, biologics, or devices within 4 weeks prior to study treatment or planned use during the course of the study.
- •Previous exposure to pralatrexate.
结局指标
主要结局
Response Rate Per Independent Central Review
时间窗: Response was assessed at 7 weeks (prior to Cycle 2) and then prior to every other even-numbered cycle (every 14 weeks) until disease progression or death for up to 2 years after initial dose
Patient response to treatment was determined by independent central review using International Workshop Criteria (IWC). Results present the best overall response. The initial response assessment was scheduled at week 7 (prior to Cycle 2) and then prior to every even-numbered cycle (every 14 weeks) for up to two years after first dose.
次要结局
- Duration of Response Per Independent Central Review(Measured from the first day of documented response, assessed at prior to every other even-numbered cycle (every 14 weeks) until disease progression or death for up to 2 years after initial dose)
- Progression-free Survival Per Independent Central Review(Calculated as the number of days from treatment day 1 to the date of disease progression or death, regardless of cause for up to 2 years after initial dose)
- Overall Survival Per Independent Central Review(Assessed every 14 weeks while on treatment, and after disease progression no less frequently than every 6 months for up to 2 years after first dose.)
研究者
研究点 (64)
Loading locations...
相似试验
已完成
2 期
Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's LymphomaLymphoma, B-CellNCT00998946Spectrum Pharmaceuticals, Inc29
已完成
2 期
Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary BladderCarcinoma, Transitional CellBladder NeoplasmBladder CancerNCT00722553Acrotech Biopharma Inc.30
已完成
2 期
Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)Head and Neck CancerNCT01183065Memorial Sloan Kettering Cancer Center13
已完成
1 期
Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell LymphomaPeripheral T-cell LymphomaNCT02013362Mundipharma K.K.25
已完成
1 期
Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal CancerFallopian Tube CancerPeritoneal CancerOvarian CancerNCT01188876Massachusetts General Hospital50